A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Table of Contents Incyte is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics. Our global headquarters is located in Wilmington, Delaware, where we conduct discovery, clinical development and commercial operations. We also conduct clinical development and commercial operations from our European headquarters in Morges, Switzerland, and our other offices across Europe, as well as our Japanese headquarters in Tokyo and our Canadian headquarters in Montreal. We are focused in three therapeutic areas that are defined by the indications of our approved medicines and the diseases for which our clinical candidates are being developed. These therapeutic areas are: Hematology, Oncology, and Inflammation and Autoimmunity (“IAI”).
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 5.1B | 5.1B | 4.2B | 3.7B | 3.4B | 3.0B |
| Net Income | 1.3B | 1.3B | 33M | 598M | 341M | 949M |
| EPS | $6.41 | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 |
| Free Cash Flow | 1.4B | 1.4B | 321M | 491M | 892M | 568M |
| ROIC | 55.5% | 27.2% | 5.5% | 8.6% | 28.2% | 50.3% |
| Gross Margin | 92.8% | 92.8% | 92.6% | 93.1% | 93.9% | 94.9% |
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 1.5B | 1.5B | 61M | 621M | 579M | 586M |
| Operating Margin | 29.5% | 29.5% | 1.4% | 16.8% | 17.1% | 19.6% |
| ROE | 24.9% | 29.9% | 0.9% | 11.5% | 8.4% | 29.7% |
| Shares Outstanding | 201M | 201M | 217M | 226M | 224M | 222M |
INCYTE CORP passes 7 of 9 quality checks, indicating strong fundamentals.
INCYTE CORP trades at 14.9x trailing earnings, compared to its 15-year median P/E of 23.7x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 13.5x vs a median of 28.8x. The company's 5-year average ROIC is 24.0% with a gross margin of 93.5%. At current prices, the estimated annualized return to fair value is +18.6%.
INCYTE CORP (INCY) has a current P/E ratio of 14.9, compared to its historical median P/E of 23.7. The stock is currently considered Fair based on its historical valuation range.
INCYTE CORP (INCY) has a 5-year average return on invested capital (ROIC) of 24.0%. This indicates strong capital allocation and a potential competitive advantage.
INCYTE CORP (INCY) has a market capitalization of $19.2B. It is classified as a large-cap stock.
INCYTE CORP (INCY) does not currently pay a regular dividend.
Based on historical P/E analysis, INCYTE CORP (INCY) appears fair. The current P/E of 14.9 is 37% below its historical median of 23.7. The estimated fair value CAGR (P/E method) is 15.2%.
INCYTE CORP (INCY) operates in the Services-Commercial Physical & Biological Research industry, within the Industrials sector.
INCYTE CORP (INCY) reported annual revenue of $5.1 billion in its most recent fiscal year, based on SEC EDGAR filings.
INCYTE CORP (INCY) has a net profit margin of 25.0%. This is a strong margin indicating high profitability.
INCYTE CORP (INCY) generated $1.4 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
INCYTE CORP (INCY) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
INCYTE CORP (INCY) reported earnings per share (EPS) of $6.41 in its most recent fiscal year.
INCYTE CORP (INCY) has a return on equity (ROE) of 29.9%. This indicates the company generates strong returns for shareholders.
INCYTE CORP (INCY) has a 5-year average gross margin of 93.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for INCYTE CORP (INCY), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
INCYTE CORP (INCY) has a book value per share of $25.74, based on its most recent annual SEC filing.
No recent press releases.